Sign up to save your podcasts
Or
Share Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL
In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function shifts away from hemostasis and toward a more immunomodulatory role. These finding could have important implications for transfusion medicine and certain platelet-related disease states. After that, use of odronextamab, a CD20×CD3 bispecific antibody, in patients with diffuse large B-cell lymphoma, or DLBCL, progressing after CAR T cell therapy. The study is the first to evaluate the efficacy and safety of this therapy in the post-CAR T cell treatment setting. Finally, we will recap findings from a study of a novel CAR T-cell product that utilizes specificity to two antigens common in diffuse large B-cell lymphoma.
Featured Articles:
- Aging platelets shift their hemostatic properties to inflammatory functions
- Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
- Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma
View all episodes
By American Society of Hematology
4.1
4949 ratings
In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function shifts away from hemostasis and toward a more immunomodulatory role. These finding could have important implications for transfusion medicine and certain platelet-related disease states. After that, use of odronextamab, a CD20×CD3 bispecific antibody, in patients with diffuse large B-cell lymphoma, or DLBCL, progressing after CAR T cell therapy. The study is the first to evaluate the efficacy and safety of this therapy in the post-CAR T cell treatment setting. Finally, we will recap findings from a study of a novel CAR T-cell product that utilizes specificity to two antigens common in diffuse large B-cell lymphoma.
Featured Articles:
- Aging platelets shift their hemostatic properties to inflammatory functions
- Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
- Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma
More shows like Blood Podcast
View all
TED Talks Daily
11,155 Listeners
JAMA Editors' Summary
139 Listeners
NEJM This Week
318 Listeners
JAMA Clinical Reviews
499 Listeners
Hematologic Oncology Update
75 Listeners
The Hematologist
26 Listeners
Core IM | Internal Medicine Podcast
1,156 Listeners
VJHemOnc Podcast
2 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
363 Listeners
The Curious Clinicians
372 Listeners
EHA Unplugged
1 Listeners
Blood Cancer Talks
48 Listeners
Two Onc Docs
189 Listeners
WolverHeme Happy Hour
30 Listeners
HemeTalks: Conversations in Hematology Education
4 Listeners